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Abstract (95 words) 27 
The poor outcomes in esophageal adenocarcinoma (EAC) prompted us to interrogate the 28 
pattern and timing of metastatic spread. Whole genome sequencing and phylogenetic 29 
analysis of 388 samples across 18 EAC cases demonstrated in 90% of cases that multiple 30 
subclones from the primary tumor spread very rapidly from the primary site to form 31 
multiple metastases, including lymph nodes and distant tissues, a mode of dissemination 32 
that we term ‘clonal diaspora’. Metastatic subclones at autopsy were present in tissue and 33 
blood samples from earlier time-points. These findings have implications for our 34 
understanding and clinical evaluation of EAC.   35 
 36 
Introduction 37 
Metastatic spread to distant sites accounts for the majority of cancer deaths1. 38 
Understanding the anatomical extent of disease is essential to determine the optimum 39 
treatment strategy. This is challenging since cancer continually evolves at a microscopic 40 
scale, often beyond the resolution of clinical imaging techniques. Furthermore, the patterns 41 
of metastatic spread are often unpredictable in terms of time-course and anatomical 42 
location. Treatments may therefore be unnecessarily toxic (e.g. radical lymphadenectomy 43 
and chemotherapy) or insufficiently aggressive, leading to high recurrence rates2-4. 44 
Esophageal cancer is the sixth most common cause of cancer-related death worldwide and 45 
the current median survival time is still <1 year5. Incidence rates for esophageal 46 
adenocarcinoma (EAC) have risen sharply and it is now the predominant subtype in 47 
developed countries. Prognosis is highly variable for EAC patients as shown by the wide 48 
range of 5-year survival (18-47% with lymph node involvement), making it difficult to advise 49 
patients when embarking on a long course of grueling treatment2,6.   50 
Theoretical and experimental studies attempt to understand how tumor cell populations 51 
respond to selective pressures over time7. A number of models of tumor evolution have 52 
been proposed, including linear, branching, neutral and punctuated evolution, but the 53 
extent to which these are specific to a given cancer type or co-occur is controversial8,9.  54 
Genome sequencing studies have attempted to delineate different models of evolution10. 55 
However, many of these studies have focused solely on evolution within the primary site, 56 
and knowledge of how genetic diversity emerges during metastasis remains limited. The 57 
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lack of understanding is in part due to the practical challenge of collecting multiple samples 58 
over space and time from advanced stage cancer patients.  59 
To better understand the evolution of EAC, we designed a prospective study with extensive 60 
sampling over time including samples from diagnosis, surgery and at warm autopsy (Figure 61 
1). We used whole genome sequencing (WGS) at high depth (50x), to identify mutations, 62 
and at shallow (1x) coverage, to track known variants, to interrogate the clonal architecture 63 
across time and space.  64 
 65 
Results 66 
Genomic architecture of 18 cases  67 
Eighteen cases were included in the study and the clinical demographics of these cases are 68 
shown in Supplementary Table 1 and 2, with details of the individual samples given in 69 
Supplementary Table 3 and 4. In the first part of the study (Figure 1a, Extended Data Fig. 70 
1,2) we used 50x WGS to construct a phylogenetic tree for each case, to understand the 71 
relationship between the primary and metastatic tumors (Figure 2, Extended Data Fig. 3 , 72 
Supplementary Figure 1, Supplementary Table 3, 4). Mutation clustering was performed, 73 
and the fractions of tumor cells carrying each set of mutations (Cancer Cell Fraction, CCF) 74 
within each sample were used to determine: 1) the clonal and sub-clonal architecture of 75 
each tumor (subclonal CCF <95%, clonal CCF > 95%); 2) the hierarchy of events; and 3) the 76 
distance of these sub-clonal or clonal clusters from the most recent common ancestor 77 
(MRCA) (Figure 1a, Extended Data Fig. 1,2). The CCF and number of single nucleotide 78 
variants (SNVs) associated with each clone and subclone are shown in Supplementary Table 79 
5 and 6, as is the tumor purity of each sample using the Battenberg algorithm11, in 80 
Supplementary Table 7 and the confidence intervals of the clonal and subclonal CCFs in 81 
Supplementary Table 8.  Detailed information on experimental design is provided in the Life 82 
Sciences Reporting Summary.  83 
These analyses enabled us to construct phylogenetic trees (Methods). In all cases we 84 
observed a long trunk compared to the rest of the tree (median 19,034 SNVs, IQR 11,299-85 
63,908), consistent with previous studies in EAC12,13. The median size of clonal or subclonal 86 
clusters across all cases was 3,069 SNVs (IQR 1332-63908) and only 2/157 contained fewer 87 
than 200 SNVs (S1_3 and P5_11), Extended Data Fig. 3 and Supplementary Table 6. 88 
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The key driver events14,15 are depicted on each phylogenetic tree (Figure 2 and Extended 89 
Data Fig. 3). The events identified as most frequent in previous studies occurred in the 90 
trunks of the phylogenetic trees, consistent with their previous classification as drivers. TP53 91 
was mutated in the trunk of 16 out of 18 cases, consistent with our knowledge of the 92 
disease14,16-19. Amplifications (gene names in red) were often truncal, but also observed on 93 
the branches of the phylogenetic tree, providing evidence of divergence during later 94 
evolutionary stages (Figure 2, Extended Data Fig. 3). The majority of events in driver genes 95 
were copy number alterations (CNAs) rather than SNVs or InDels (Figure 2, Extended Data 96 
Fig. 3)14,19,20. There was no significant difference in the overall number of structural variants 97 
between primary and metastatic samples (p=0.41, generalized linear model; Extended Data 98 
Fig. 4b). However, a larger proportion of structural variants in metastatic samples were 99 
retro-transpositions of mobile elements than in the primary samples (p=0.045, Extended 100 
Data Fig. 4c). This contrasts with pancreatic cancer, where deletions and fold-back 101 
inversions are more common in metastases, and breast cancer where tandem duplications 102 
dominate21. Interestingly, the high rate of L1 transposon activity in EAC has recently been 103 
associated with high activity in the germline22. Our results suggest a further increase in L1 104 
activity in metastatic EAC. Furthermore, the proportion of structural variants found uniquely 105 
in metastases or in primary sites was higher than that of SNVs (Figure 2, Extended Data 4a), 106 
suggesting an increase in genomic instability in later stages of the disease. However, it 107 
cannot be ruled out that some structural variants have not been identified in every sample 108 
as a result of lower sensitivity in the detection of structural variants than SNVs. 109 
Across the eighteen cases, 8 mutational signatures were observed, consistent with previous 110 
studies23-26 (Figure 3a), with varying prevalence across the cases. None of the signatures that 111 
we observe in patients in our cohort who had oncologic therapy have been associated with 112 
treatment with alkylating antineoplastic agents27, platinum therapy28 or radiation therapy29.  113 
 114 
Early seeding of oligometastases 115 
Ten of eighteen patients (S3, S4, P1-4, P6, P8-10) had both nodal and solid organ 116 
metastases, allowing a direct comparison of the genomic architecture between different 117 
metastatic sites (Figure 2).  118 
In four of these ten cases, an isolated clone or subclone confined to 1 or 2 distant 119 
metastases, i.e. an oligometastasis, depicted as a dashed black node on the first branch of 120 
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the phylogenetic tree, shared the highest congruence to the MRCA, (P1, P4, P10, S3 in 121 
Figure 2; Subclones P1_2, P4_3, P10_2, S3_2 in Supplementary Table 5). In P1, this clone 122 
(P1_2) was observed only in the primary tumor and a pleural metastasis. In S3 and P4, the 123 
clone involved in this isolated seeding was identified at a single distant site and not in the 124 
primary tumor (S3_2: liver metastasis (D1), P4_3: para-aortic lymph node (L3)). In P10, the 125 
early seeding clone (P10_2) was shared between a distant para-aortic node and a sub-clonal 126 
metastasis in the right hemi-diaphragm. The subclones associated with these isolated 127 
seeding events showed little divergence from the MRCA across these 4 cases (median 1,913 128 
SNVs, range 832-8,591), suggesting early seeding to distant metastases. Notably, in P9 a 129 
subclone (P9_10, Supplementary Table 5) was found in a premalignant area of Barrett’s 130 
esophagus and a pleural metastasis but not in any of four areas of the primary tumor 131 
subject to 50x WGS. This subclone lineage shares no variants with the main lineage and 132 
appears to be an independent second cancer (Figure 2). 133 
A single clone gives rise to multiple metastatic sites 134 
A striking observation was that 9/10 cases had a clone (outlined in red on the phylogenetic 135 
tree in Figure 2) that was followed by dispersion of multiple subclones from the primary to 136 
discrete metastatic sites, resulting in a model of metastasis that we term ‘clonal diaspora’. 137 
In most cases, this dispersion was visually stellate in nature, this being defined as a feature 138 
of a phylogenetic tree involving 3 or more branches leading from a single founder clone (see 139 
details in Discussion). The subclones forming diasporas were located in both primary and 140 
metastatic tissue in eight cases (P1, P2, P3, S4, P4, P6, P8, P10) and in P9 were unique to 141 
metastases (Figure 2). The only two cases lacking a stellate pattern on the phylogenetic tree 142 
were P10 and S3. The latter is a non-autopsy case with limited tissue sampling and the early 143 
distant seeding in this case is consistent with a pattern of parallel evolution (Figure 2).  144 
 145 
Subclonal spread is not constrained by location or tissue  146 
In the second step of the study we tracked the spread of metastases across a wider range of 147 
lymph node and distant tissue sites by performing 1x WGS in a further 248 tissue samples 148 
from 6 autopsy cases (Figure 1a,c).  We did not call new mutations, as this would not be 149 
possible at 1x sequencing, but used this method to detect the spread of clones and 150 
subclones previously identified using 50x WGS (bioinformatic validation of methods in 151 
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Extended Data Fig. 5 and 6, Supplementary Note; wet lab validation in Extended Data Fig. 7, 152 
Supplementary Table 9). The samples used in this part of the study are outlined in 153 
Supplementary Table 10. The median size of subclonal and clonal clusters (identified 154 
previously at 50x WGS) that we aimed to detect using 1x WGS was 3,784 (IQR 1,966-49,955). 155 
Sample sites were grouped according to their similarity based on the presence of subclones 156 
and clones previously detected with 50x WGS (Supplementary Note). The resulting groups 157 
of samples are color coded and numbered, and each sample site, colored by group, is shown 158 
on the adjacent body map (Figure 4, see also Supplementary Note). Notably, the samples 159 
that grouped together based on shared clonal origins were widely dispersed anatomically.  160 
Four out of six cases with extensive spatial sampling (Figure 4) had liver metastases 161 
evaluated and three of these contained samples that were more similar to local lymph node 162 
metastases than neighboring liver metastases (P4, P6, P8 but not P10). The high number of 163 
groups within the liver (up to four) suggested seeding by multiple subclones (seen in P4, P6, 164 
P8), whereas the single group in the liver of P10 (orange, group 3) indicated seeding by a 165 
common progenitor or a set of closely related cells. 166 
A comparison of lymph node location and genomic contiguity showed no evidence of 167 
tropism, i.e. genomically similar lymph nodes did not occupy nearby anatomical locations. 168 
Lymph nodes above and below the diaphragm were frequently seeded from common 169 
events (P2: groups 1, 3; P4: groups 5, 6; P6: group 5; P8: groups 2, 3,5, 6; P10: group 4), at 170 
odds with a progression from local to distant nodes. Similarly, a comparison of lymph node 171 
and solid organ metastases showed scant evidence for tropism, with the exception of P1 172 
(Supplementary Note). This patient underwent surgical resection and subsequently had 173 
metastatic disease recurrence.  In this cancer, separate subclones seeded lymph node and 174 
pleural metastases (Figure 2, 4). Notably, the distant metastasis (D1) was an early branching 175 
oligometastasis whereas the lymph nodes (L1, L2) constituted the later diaspora event 176 
(black and red circles, respectively, in Figure 2).  177 
We further traced regions of the primary tumor at autopsy that had similar subclonal 178 
compositions to each of the metastases, shown as adjacent tumor maps (Figure 4, bottom 179 
left of each case). Subclones occupied spatially distinct areas in the primary tumor. 180 
We also looked for driver amplifications post MRCA or post diaspora on a per case basis and 181 
identified selection in 6/10 cases. However, this is likely to be an under-estimate, since there 182 
may be non-copy number drivers present in additional cases.  The ratio of non-synonymous 183 
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to synonymous SNVs (dN/dS) was analyzed across all cases in order to assess the presence 184 
or absence of positive selection30. Results indicated positive selection in both clonal and 185 
subclonal genomes, albeit with lower levels of selection within subclones (Extended Data 186 
Fig. 8). 187 
 188 
Metastatic spread is rapid in EAC 189 
To examine the timing and speed of metastatic spread we analyzed base substitution 190 
mutational signatures, particularly the aging signature which features a predominance of 191 
C>T transition in the NpCpG trinucleotide context (Figure 1a, Figure 3).  192 
Signature 1 arises from the spontaneous or enzymatic deamination of methylated cytosines, 193 
which is an endogenous process that occurs continuously in both healthy and cancerous 194 
cells. This has been shown to act as a molecular clock27,31-35, and was therefore used here as 195 
a method to examine the temporal relationship between metastases. Using a previously 196 
described method for deconvolving mutational signatures35, we observed that signature 1 197 
was present in the trunk but absent in all subclones that constituted diaspora (following the 198 
red parental clone in Figure 2) for P2, P4, P6, P9, P10, S4 and it was significantly reduced for 199 
P1 (21% to 3%) and P3 (16% to 9%) (Wilcoxon signed rank test p=0.039, Figure 3c). To 200 
account for the possibility that the number of signature 1 mutations in branch subclones 201 
was below the resolution of our deconvolution methods, we also identified the number of 202 
mutations with the characteristic feature of signature 1, i.e. C>T mutations in a CpG context. 203 
To estimate the time of appearance of diaspora, we compared the number of these 204 
characteristic mutations that occurred along the trunk to the parental red clone marking the 205 
onset of diaspora with those that occurred on the longest branch leading from this point. 206 
The median proportion of such mutations occurring prior to the onset of diaspora was 0.911 207 
(Figure 3b). Thus, in the majority of cases one might deduce that little time has elapsed 208 
between the appearance of the cell that is ancestral to disseminating cells and the individual 209 
cells that seeded each of the metastases. With the exception of P8, the proportion of 210 
mutations attributed to signature 1 was significantly lower after the parental (red) clone on 211 
the phylogenetic tree (p<9.1 × 10-5, Chi-squared test across all cases; Figure 3c) suggesting 212 
an increase in the activity of other processes in later evolutionary stages (Supplementary 213 
Table 11). Of note, there was an increase in the proportion of signature 3 in subclonal SNVs 214 
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compared to clonal SNVs (Wilcoxon signed rank test p=0.019, Figure 3b), suggesting failure 215 
of DNA double strand break repair is predominantly a late-stage event in EAC.  216 
 217 
Early detection from diagnostic samples    218 
Next, we investigated eight cases (P1-4, P6, P8-10) for which the esophageal diagnostic FFPE 219 
biopsy or surgical sample (primary tumor at resection for P1 and lymph node from surgery 220 
for P9) were available, with a median time prior to autopsy of 12 months (range 5-30 221 
months) (Figure 1). The diagnostic sample for P1 was snap frozen and sequenced to 50x 222 
(Figure 2; highlighted with * in Extended Data Fig. 9), while 1x WGS was performed on the 223 
remainder of the cases. Between 8% and 36% of the subclones and clones observed in 224 
samples taken from autopsy were also present in the diagnostic samples (Supplementary 225 
Note and Extended Data Fig. 9). In six cases, all subclones identified from the biopsy samples 226 
were also found in the primary samples from autopsy. Two diagnostic endoscopic samples 227 
from P4 also contained many of the mutations found in the lymph node L2 at autopsy, 228 
which had not been previously identified in the primary tumor at autopsy (Figure 2, 229 
subclone P4_17, Supplementary Table 5). Similarly, the biopsy sample from P10 contained a 230 
substantial number of mutations from both the oligometastasis that seeded D2 and L4 231 
(Supplementary Table 5, P10_2), and the lineage that later metastasized to multiple sites 232 
(Figure 2). Notably, P4 and P10 had shorter survival times after diagnosis than the remaining 233 
patients (5 and 4 months, respectively). 234 
 235 
Plasma sample analysis at autopsy and earlier time-points 236 
We assessed the clonal composition of circulating tumor DNA (ctDNA) at earlier time-points 237 
in seven blood samples from five cases (Figure 1, Figure 5a,c; Extended Data Fig. 10, 238 
Supplementary Table 12). Combined 1x WGS subclone/clone detection, copy number 239 
aberrations and TP53 fraction using digital PCR data are displayed for two of these cases (P6 240 
and P10) in Figure 5a. Notably, P6 was a patient being treated with curative intent and had 241 
no radiological evidence of distant nodal or organ metastases at the time of clinical staging. 242 
However, at the time of diagnosis mutations from the truncal cluster and three subclonal 243 
clusters later found in the metastases were already present in the plasma (Figure 5a) along 244 
with amplifications in MYC and GATA4. Case S4 is noteworthy as the brain metastases (D1, 245 
D2 in Figure 2) appeared to have originated from a subclone shared between the primary 246 
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and a local lymph node, both of which were removed at the time of surgery (Extended Data 247 
Fig. 10c). However, mutations from the truncal cluster and four subclonal clusters were 248 
already present in ctDNA prior to radiological recurrence. 249 
In eight cases, plasma was available from rapid autopsy. One case (P3) failed wet lab SNV 250 
validation and was hence removed from the SNV subclone analysis (Supplementary Note).  251 
Analysis of ctDNA demonstrated that in all cases the truncal cluster from autopsy was also 252 
represented in plasma (Figure 5c). In addition, mutations from between 0 and 7 subclonal 253 
clusters were identified from plasma (Figure 5c). The ratio of mutations detected from each 254 
subclone was very consistent between blood from earlier time points and autopsy (Pearson 255 
r range [0.851, 0.994], maximum P-value 8.9 × 10-4) and in 2 of 5 cases the proportion of 256 
mutations detected was higher in the earlier sample, suggesting an opportunity for earlier 257 
detection of heterogeneous cancer cell populations. Further, subclonal proportions 258 
estimated from exome sequencing of plasma samples were highly correlated with those 259 
from 1x WGS (Supplementary Table 9). 260 
The majority of driver CNAs identified in the MRCA of each tumor from 50x WGS of tissue 261 
samples were also identified in plasma both at autopsy and at earlier time-points (Figure 262 
5a,b). In addition, MET amplification, which was not present in the MRCA in P1 (Figure 2), 263 
was identified in plasma both at autopsy and an earlier time point (Extended Data Fig. 10a), 264 
suggesting opportunities for early detection of metastatic subclones. Notably, however, 265 
amplifications found only in oligometastases or in post-diaspora subclones from 50x 266 
sequencing were not identified in plasma, despite many of them being detected in 1x 267 
sequencing of tissue samples (Figure 5b). A plausible explanation for this observation is that 268 
each of the many metastasizing subclones contributed insufficient material to the sum of 269 
detected ctDNA to enable confident detection of CNAs. 270 
 271 
Discussion 272 
We have gathered multiple lines of evidence which suggest that, for the majority of EACs, a 273 
complex mode of spread is operative. These lines of evidence can be summarized as follows 274 
(Figure 6). We observe multiple subclones, each seeding multiple metastatic sites. These 275 
subclones are frequently derived from a single parental clone, generally resulting in a 276 
stellate pattern on the phylogenetic tree. Metastases in solid organs can bypass nodal 277 
involvement and samples within solid organ sites frequently resemble distant metastases 278 
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more closely than neighboring metastases within the same organ, i.e. no tropism is 279 
observed. All metastases appear to have spread directly from the primary site, with little or 280 
no evidence of metastasis-to-metastasis seeding.  281 
These features differ in some important respects from previously described models of 282 
metastasis and we propose that they may constitute a distinct, additional model of 283 
evolution. We suggest that this pattern be referred to as a ‘diaspora’, by extension of the 284 
anthropological term to cancer36. Within this context, it is associated with the observation 285 
that multiple cell populations in metastatic sites are directly linked to the primary site of 286 
origin and that individual subclones seed multiple tissue types, analogous to a diaspora 287 
crossing multiple national boundaries. 288 
A number of features were frequently associated with this phenomenon (Figure 6), with 289 
nine of the cases (all except S3) displaying at least two of the four following features: i) 290 
stellate pattern on the phylogenetic tree defined as three or more subclones emerging from 291 
the founder clones; ii) lack of signature 1 mutations post MRCA or post-diaspora; iii) spread 292 
of subclones to multiple organs of different type; iv) evidence for selection in post diaspora 293 
genotypes.  294 
Until recently the genomic architectures of metastatic samples have not been defined with 295 
enough resolution to discern temporal or spatial patterns of metastatic spread. Several 296 
distinct patterns are now emerging which are not necessarily mutually exclusive or cancer-297 
type specific. In pancreatic cancer, Yachida et al. demonstrated that distant organ seeding 298 
was a late event consistent with a linear progression model24. In prostate cancer, linear 299 
progression is often succeeded by multiple waves of seeding37. The same study further 300 
demonstrated widespread subclonal evolution in metastases and metastasis-to-metastasis 301 
spread, in keeping with the relatively long longevity of prostate cancer. Strikingly, a stellate 302 
pattern was not observed in any of the cases in that study, despite using a similar design to 303 
that used here. 304 
In Supplementary Table 13 we compare the features of our proposed Diaspora model to the 305 
previously posited linear38 and parallel8 models. Whereas the linear model predicts that a 306 
single subclone seeding lymph node sites is followed by transmission to distant organs, the 307 
diaspora model posits simultaneous seeding of multiple sites directly from the primary. 308 
Unlike the parallel model, the diaspora model implies that metastasis formation occurs after 309 
the majority of evolution has occurred in the primary tumor, resulting in multiple subclones 310 
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found in common between primary and metastatic tumors. Lymphatic and distant 311 
metastases in colon cancer have been shown to arise from independent subclones in the 312 
primary tumor with disparate evolutionary trajectories39. In contrast, in EAC we find that 313 
individual subclones frequently seed both lymph node and distant organs suggesting that 314 
disparate trajectories for nodal and solid organ metastases do not exist for this disease 315 
(Figure 2, 3). Of note we acknowledge that, despite the extensive and systematic sampling 316 
across all autopsy cases, further sampling may add further branches to our phylogenetic 317 
tree, although this is unlikely to affect the diaspora event itself. 318 
In common with the Big Bang Model proposed for colorectal cancer40, our model predicts 319 
the occurrence of highly branching phylogenies. However, the Big Bang Model proposes 320 
neutral dynamics, whereas we observe strong evidence for selection in subclonal 321 
populations in the form of dN/dS ratios and the occurrence of subclonal driver 322 
amplifications (Figure 2, Extended Data Figure 8, Supplementary Figure 2). Moreover, the 323 
clonal maps of the primary tumor demonstrate subclones that occupy spatially discrete 324 
areas of the primary tumor (Figure 4), in contrast to the intermixed subclones predicted by 325 
the Big Bang Model40.  326 
The sequence of events in metastatic progression may have clinical implications that require 327 
further study (Supplementary Table 13). Clonal architecture in EAC defies anatomical 328 
location of lymph node stations and distant sites, which is the current basis for the TNM 329 
staging and determines whether curative therapy is appropriate. It has been suggested that 330 
the high recurrence rate, 52% within one year, results from seeding of distant metastases 331 
that are not detected at the time of diagnosis26. This study provides molecular evidence for 332 
this observation and highlights the need for different systemic approaches to disease 333 
management, including consideration of more aggressive adjuvant therapy which is not 334 
currently the mainstay of treatment41-44. With advances in the sensitivity of ctDNA assays, 335 
metastatic subclones may be detectable in the blood, helping to determine when systemic 336 
therapy is required post-surgery and in detecting heterogeneity of acquired resistance45.  337 
Copy number variation in plasma may also be a future early detection strategy46. 338 
 339 
The occurrence of metastasis is a pivotal event in the life history of a cancer. Understanding 340 
the drivers behind such an event would have potential relevance to patient stratification 341 
and predicting and preventing metastatic spread47. While we have identified many drivers 342 
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on the trunks of the trees, prior to diaspora (Figure 2), we cannot be certain which event, if 343 
any, was the immediate trigger of diaspora in individual cases. In a number of cases, 344 
diaspora was coincident with an increase in the proportion of signature 3 mutations, 345 
associated with failure of DNA double-strand break-repair by homologous recombination 346 
(Figure 3b). Our findings are in keeping with the failure of DNA repair driving the 347 
appearance of genomic heterogeneity. Whether the heterogeneity observed is itself the 348 
driver of diaspora or merely a symptom is an important area for future study. Our 349 
investigations of the potential drivers of diaspora were limited to genomic factors, and 350 
further multi-platform studies looking at epigenetic and transcriptomic factors are other 351 
important avenues of future research. We anticipate that analyses of single cells or small 352 
clusters from primary sites, disseminated tumor cells and circulating tumor cells will also 353 
yield finer resolution of the processes of dissemination and metastasis.  354 
In cancer there are currently very few in-depth studies examining the spatial and temporal 355 
evolution of metastases48. Further studies are required to ascertain the extent to which our 356 
diaspora theory pertains to other cancers.  357 
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Figure Legends 515 
Figure 1 Overall project strategy and study design 516 
a. Overall Strategy to identify clonal evolution in metastatic EAC. There were three main 517 
steps in this study which comprised: Clonal discovery at autopsy (see Supplementary Note 518 
High Depth Whole Genome Sequencing (50x WGS), Mutation clustering and phylogenetic 519 
tree construction, dN/dS analysis and Mutational Signature Analysis); Spatial tracking at 520 
autopsy (see Supplementary Note Shallow Whole Genome Sequencing (1x WGS) and 521 
Temporal tracking at earlier time-points (see Supplementary Note Shallow Whole Genome 522 
Sequencing (1x) for Subclone identification, Supplementary Table 12 for precise samples for 523 
plasma and Extended Data Fig. 9 for FFPE diagnostic samples). Colored circles depict clones 524 
and subclones respectively. b. Sampling Strategy at Rapid Autopsy. Areas sampled for the 525 
50x WGS part of the study are shown in blue and for 1x WGS are shown in orange.  c. Study 526 
Design and Sequencing Strategy. The flow chart demonstrates the study design and how this 527 
relates to sequencing. Clonal Discovery is in blue and Clonal Tracking in orange. The sample 528 
distribution for 50x WGS and 1x WGS are shown. 50x WGS = High depth WGS (50x), 1x WGS 529 
= Shallow WGS (1x). n = number of cases, s = number of samples. †=248 solid tissue 530 
samples, and 8 ctDNA at autopsy. CNA, copy number alteration; SNV, single nucleotide 531 
variant; MRCA, most recent common ancestor. 532 
Figure 2 Phylogenetic Analysis of ten cases with nodal and distant metastases 533 
Patient body maps (S=surgical case, P=rapid autopsy) are shown. Green circles denote 534 
lymph node metastases and yellow circles distant metastases. The labels within each circle 535 
describe the specific location (see Supplementary Table 3, 4). An organ is shown in color if 536 
metastases were sequenced from that site. The adjacent wedged semi-circle depicts the 537 
clinical timelines for each patient. Each wedge corresponds to one month; blue wedges 538 
indicate the total lifetime of the patient and red wedges periods of therapy. Phylogenetic 539 
trees for each patient are shown and methodology is in Supplementary Note and Extended 540 
Data Fig. 1a-b; pink = truncal events shared by all samples, purple = branch events shared by 541 
more than one sample, yellow = leaves, events unique to a sample. The circle at the end of 542 
a trunk, branch or leaf represents a clone or subclone. Each clone or subclone is annotated 543 
to show which samples it is present in. E1-E4 = primary esophageal tumor, L1-L4= lymph 544 
nodes, D1-8 =distant metastases, B = Barrett’s Esophagus.  A subclone annotated with E1, L2 545 
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for example indicates that this subclone is seen only in samples E1 and L2. The CCF of each 546 
subclone/clone (barring the MRCA) is in Supplementary Table 5 and 6. The length of the 547 
branches of the tree are reflective of the number of SNVs in the subclone/clone. The scales 548 
adjacent to each case are relative, given the variable number of SNVs per case. Trees are 549 
annotated with potential driver events, black: missense variants, red: amplifications. Gray 550 
dots outlined with a black dashed line denote the first subclone/clone to metastasize that 551 
would be classified as non-curative based on anatomical location. Red dots mark the 552 
stellate pattern on the phylogenetic tree.  553 
Figure 3 Mutational Signatures 554 
a. Contributions of mutational signature in 18 cases (n=122) across the cohort. The bar chart 555 
displays samples on a per case basis (X-axis) and depicts the number of SNVs contributing to 556 
each signature (Y-axis). b. Mutational signatures pre-and post- diaspora across all samples 557 
(n=122) in 18 cases. 558 
Mutations were separately assigned to signatures and the proportion of mutations within 559 
each case assigned to each signature is shown. Dark lines = median, Boxes = 25th and 75th 560 
quartiles, whiskers extend to the most extreme point within 1.5× interquartile range of the 561 
box edge. Signatures 1 mutations have a significantly lower representation in post-diaspora 562 
mutations, while signature 3 mutations have significantly high. c. Mutational signature 563 
analysis of ageing signature (signature 1) pre-and post-diaspora in all cases (n=8) with local 564 
and distant spread (p<1.18 × 10-90 across all cases) Chi squared test was used to determine 565 
the p value. Survival is shown in months from the point of diagnosis *=cases which 566 
underwent surgery.  567 
 568 
Figure 4 1x WGS and similarity matrix clustering of 248 further tissue samples from six 569 
cases 570 
1x WGS was performed at an average depth of 1x to track subclones and clones previously 571 
discovered using 50x WGS for further tissue samples (n=248). Pearson correlation 572 
similarity matrix clustering was performed on all samples for each case (plotted against 573 
each other) with red indicating sample similarity (r=1) and blue indicating dissimilarity (r=-574 
1). Sample sites used in this part of the study are shown in Supplementary Table 9 and the 575 
entire organ is highlighted if solid organ sites were sequenced. For example, liver 576 
metastases were only seen in P4, P6, P8, P10. Similarly, P2 had lymph nodes only (only 577 
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colored dots are seen which represent lymph nodes, no solid organs are highlighted). 578 
Clustering was performed based on the presence of subclones and clones already 579 
detected using 50x WGS and distinct clusters were identified for each case as 580 
demonstrated by the adjacent key per case (each group is both colored and numbered). 581 
Samples are displayed on the adjoining body maps for which the color coding corresponds 582 
to the genomic clustering in the adjacent heatmap. Sites with multiple samples are 583 
magnified and the division of samples shown. Maps of the primary tumor with 584 
representation of metastatic subclones are shown with each case, with the colors of the 585 
subclones being the same as those in the matrix and body map. Areas shaded red in the 586 
primary tumor represent subclones that were not detected in the metastatic samples that 587 
underwent 1x WGS and were instead confined to areas of the primary tumor.  588 
 589 
Figure 5 Temporal and spatial tracing of metastatic subclones in plasma  590 
a. Plasma ctDNA 1x WGS and digital droplet PCR (ddPCR) analysis for TP53 mutant allele 591 
fraction (MAF) for P10 and P6. The MAF of TP53 (%) is shown on the Y-axis and days from 592 
diagnosis are shown on the X-axis. The shaded areas represent time periods of therapy. 1x 593 
WGS at select time-points was performed and the clonal composition of these samples 594 
are shown by the presence of colored clusters. The color of each corresponds to the color 595 
of the corresponding node on the adjacent 50x phylogenetic tree with the presence of 596 
colored clusters which correlate with the 50x tree.  Moreover, copy number traces for 597 
each time point are shown for select chromosomes. b. The presence or absence of 598 
amplifications and deletions in plasma compared to tissue, detected from 1x WGS for 8 599 
cases.  Tissue refers to all samples collected at autopsy and at earlier time-points. c. 600 
Stacked bar charts to demonstrate the presence or absence of clusters across all plasma 601 
samples, including truncal and branch clusters using 1x WGS.  602 
 603 
Figure 6 Diaspora model of metastatic spread and associated features  604 
Panel a depicts clonal diaspora with colored circles representing clones and subclones. *= 605 
evidence of selection. Panel b explains the five features seen in diaspora (one is defining, 606 
and the other are associated with diaspora) and whether these are present () or absent 607 
(x) in each case.  * implies that the feature is present, and that the evidence was from 608 
1x WGS.   609 
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Methods  610 
Statistics 611 
Unless otherwise stated, statistical analyses were performed using R, version 3.3.3. 612 
Clustering of mutations was carried out using a previously published Bayesian Dirichlet 613 
Process method, DPClust (https://github.com/Wedge-Oxford/dpclust), which calculates 614 
CCFs of each SNV, taking into account tumor purity and copy number aberrations as 615 
previously described49. Analysis of structural variants used generalized linear models, 616 
implemented with the R package MASS. Grouping of 1x WGS samples was performed with 617 
the GENE-E package (https://software.broadinstitute.org/GENE-E/download.html). 618 
Wilcoxon signed rank tests and Chi-squared tests were used as described in the main text. 619 
Simulations were used to ascertain the robustness of DPClust to violations of the infinite 620 
sites assumption and its sensitivity to detect small deviations from stellate patterns. 621 
Simulations were also used to confirm the correlation between the number of mutations 622 
detected from 1x WGS and CCF determined from 50x WGS, as described in Online Methods. 623 
dN/dS analysis was performed using the previously published package dndscv50 624 
(https://github.com/im3sanger/dndscv). 625 
 626 
Patient recruitment and Sample collection 627 
EAC patients were recruited from Addenbrooke’s Hospital, Cambridge University Hospitals 628 
NHS Trust with the explicit aim to study the clonal evolution of metastases as a sub-study 629 
within OCCAMS (Oesophageal Clinical And Molecular Stratification). When it was clear that 630 
extensive sampling of metastases could not be achieved without multiple invasive 631 
procedures, the PHOENIX autopsy study was set up (Phylogenetic of Oesophageal 632 
Neoplasia – An Investigation of Clonal Expansion under REC 07/H0305/52, and REC 633 
EE/0043) with a prospective study design. Due diligence was undertaken to ensure 634 
compliance with ethical regulations at all times.  Patients were eligible if they were at least 635 
18 years of age and had received a confirmed diagnosis of EAC following central pathology 636 
review. Patients were only approached for the PHOENIX study following a palliative 637 
diagnosis of metastatic EAC, with the full involvement of the multidisciplinary team.  638 
Samples from the PHOENIX autopsy study were obtained within 6 hours of death and all 639 
post-mortems were carried out at Papworth Hospital NHS Trust, United Kingdom. 640 
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Samples from Cambridge OCCAMS patients were obtained during diagnostic 641 
oesophagogastroduodenoscopy (OGD), at endoscopic ultrasound (EUS) and/or from the 642 
surgical resection specimen. Where possible, multiple samples were taken from spatially 643 
distinct sites of the primary tumor or metastases. In two cases, brain metastases were 644 
sampled at a clinically indicated craniotomy. Blood or normal squamous esophageal 645 
samples, at least 5cm distant from the tumor, were used as a germline reference. 646 
All tissue samples were snap-frozen in liquid nitrogen immediately after collection and 647 
stored at -80°C. Cancer samples were deemed suitable for DNA extraction only after 648 
consensus review of an H&E stained frozen section, from the same sample that would be 649 
sent for sequencing, by two expert pathologists who confirmed tumor cellularity at ≥70%. 650 
Samples with overall ≥70% cellularity underwent dissection of the whole surface area with 651 
a scalpel, whereas marked areas of <70% underwent macrodissection or laser capture 652 
micro- dissection aided by methylene blue staining visualized on the PALM-Zeiss 653 
microscope (Zeiss, Oberkochen, Germany). An H&E stained slide was obtained before and 654 
after extraction to confirm tumor cellularity of the microdissected section. 655 
DNA was extracted from frozen tissues using the All PrepDNA/RNA Mini Kit (Qiagen, 656 
Hilden, Germany) and from blood samples using the NucleonTM Genomic Extraction kit 657 
(Gen-Probe, San Diego, USA) according to the manufacturer’s instructions. Some samples 658 
were preserved in paraffin blocks after initially being stored in formalin. DNA from these 659 
samples was extracted using the QiAmp FFPE Kit (Qiagen). Plasma extraction (for ctDNA) 660 
was performed using the QiASymphony platform (Qiagen) as per the manufacturer’s 661 
instructions. All samples were eluted in 60μl of AE buffer and quantified using the High 662 
Sensitivity Qubit (Thermo Fisher Scientific, MA, USA). 663 
We included 388 samples, predominantly from PHOENIX, and some additional samples 664 
from surgery and endoscopy (part of esophageal ICGC).  665 
All samples were collected according to a strict SOP with quality control measures as already 666 
described. All demographic and clinical data was anonymized and stored on a central study 667 
database (OpenClinica and Labkey). The clinical characteristics of the patients are provided 668 
in Supplementary Table 1 and 2. In terms of specifics of sample collection at autopsy, the 669 
primary tumor was opened down the midline of the esophagus and the greater curve of the 670 
stomach to expose the lumen. The tumor was divided in 12 areas with sampling as shown. 671 
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The size of tumors varied per case, but the division of sampling was always kept identical to 672 
preserve reproducibility. In terms of the strategy for genomic sequencing (as per Figure 1), 673 
up to 3 lymph nodes were chosen for 50x WGS in the areas shown (cervical, regional and 674 
para-aortic) and up to 24 lymph nodes in each case (8 further lymph nodes per cervical, 675 
regional and para- aortic areas (as per the Japanese Classification of nodal staging51) were 676 
chosen for the 1x WGS part of the study. At least one metastasis per solid organ was chosen 677 
for 50x WGS and for the 1x WGS part up to 8 samples were taken per organ for further 678 
analysis. In addition, 8 samples from metastatic sites which had previously been sequenced 679 
for 50x WGS were further sequenced for 1x WGS to assess the effects of metastatic 680 
heterogeneity. 681 
 682 
Whole genome sequencing and data analysis strategy 683 
We used the Illumina HiSeq platform to perform WGS on multiple regions collected from 684 
each primary tumor, lymph node and/or solid organ metastasis (Figure 1a,b, Supplementary 685 
Table 3, 4). All DNA extractions and WGS conformed with ICGC quality control standards and 686 
required ≥70% cellularity and a matched germline sample. WGS was performed at high 687 
depth (median coverage 66.3, IQR 56.1-87.2) to discover mutations in 122 samples from 18 688 
patients (Supplementary Table 3, 4). In addition, low depth WGS (median coverage 1, IQR 1-689 
5) was performed to track these mutations spatially in up to 48 solid tissue samples per 690 
case, (total=248) and 8 ctDNA samples at autopsy. Temporal tracking was performed in 691 
cases with archival biopsy material, and where historical bloods were available 692 
(Supplementary Table 12, Figure 5, Extended Data Fig. 6). For each patient the number of 693 
subclones and the cancer cell fraction within each subclone was inferred using an extension 694 
of a previously described Bayesian Dirichlet process11 and we applied a set of previously 695 
described rules to derive a phylogenetic tree (Additional Methods52). All sequencing data 696 
have been deposited in the European Genome-Phenome Archive under accession number 697 
EGAD00001005434. TP53 analysis in cell free tumor DNA (ctDNA) was performed using 698 
Digital PCR on the Bio-rad platform (Bio-rad, California) using validated TP53 assays 699 
(Supplementary Table 14). 700 
 701 
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Mutation clustering and phylogenetic tree construction 702 
The workflow used to perform mutation clustering and phylogenetic tree construction is 703 
depicted in Extended Data Fig. 1a and illustrated with an example case, S3, in Extended 704 
Data Fig. 1b. For each patient, we inferred the number of subclones and the fraction of 705 
tumor cells within each subclone by using a previously described Bayesian Dirichlet process 706 
(BDP) to cluster mutations according to their mutation copy number49. We extended this 707 
process into n dimensions for patients with n related samples, where the number of 708 
mutant reads obtained from multiple related samples were modelled as independent 709 
binomial distributions. The BDP uses Markov chain Monte Carlo (MCMC) to sample the CCF 710 
values of the subclones in each sample. MCMC is run for 1000 iterations and outputs, for 711 
each iteration, the sampled position of each cluster, pih and the weight of each cluster, Vh, 712 
which is an estimate of the proportion of mutations assigned to that cluster. The first 200 713 
iterations are considered as a ‘burn-in’ and are not used in subsequent steps. In order to 714 
obtain the set of subclones present within a tumor and their CCF values, the following 715 
procedure was followed: 716 
• Using the aforementioned MCMC sampling of CCF values from all n samples, for 717 
every possible triplet of samples, obtain posterior density estimates of CCF using 718 
the function kde in the R package ks, with input parameters x = pih, bandwidth = 719 
0.1, w = Vh. Set gridsize such that density estimates are obtained to a resolution of 720 
0.02. Identify local peaks in the posterior mutation density as locations higher 721 
than any other gridpoint within a range of 2 gridpoints. For each local peak, define 722 
a region representing a ‘basin of attraction’, defined by a set of planes running 723 
through the point of minimum density between each pair of cluster positions. 724 
Assign each mutation to the cluster in whose basin of attraction they are most 725 
likely to fall, using CCF values from MCMC sampling. 726 
• Across the set of all possible triplets, identify sets of mutations that are assigned 727 
to the same cluster in every triplet. Estimate the CCF of each cluster as the mean 728 
CCF of the mutations assigned to that cluster. Estimate the 95% confidence 729 
intervals as the [0.025,0.975] quantiles of the mean pih values of the mutations 730 
assigned to each cluster within MCMC sampling. 731 
Finally, again using the aforementioned MCMC sampling of CCF values from all n samples, 732 
for every pair of samples, plot the mutation density, estimated using the function kde in 733 
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the R package ks, with input parameters x = pih, bandwidth = 0.1, w = Vh. 734 
Taking a conservative approach, clusters were identified as subclonal only if the 95% 735 
confidence intervals of the posterior estimate of the proportion of cells excluded the value 736 
1. Clusters containing less than 1% of all mutations identified in a tumor were not included 737 
in phylogenetic reconstruction. 738 
Occasionally, copy number states are incorrectly called in small regions of some cancer 739 
genomes. As a consequence, mutations falling in these regions have inaccurate estimates 740 
of CCF and can cause artefact clusters. Such clusters may be identified after mutation 741 
clustering since they contain a small percentage of mutations (less than 2.5%), the 742 
mutations within them are located in localized regions of the genome, and, often, they 743 
cannot be placed on the phylogenetic tree because they have discordant CCF values. We 744 
excluded these clusters from phylogenetic tree construction. The number of clusters 745 
excluded in total was seven (5 in P2, 1 in P3, 1 in P10). Two samples had low tumor content 746 
(36% in P3_E1, 14% in S5_T1). As a result, CCF estimates for subclones found in these 747 
samples are imprecise and led to violations of the sum rule (see below). The CCF values of 748 
the relevant clusters were manually corrected to enable them to be placed on the 749 
phylogenetic tree, as follows: P3_E1 only cluster adjusted from 1 to 0.85; S5_E1 truncal 750 
cluster adjusted from 0.85 to 1. 751 
To determine the most likely phylogenetic tree, we applied two rules, previously 752 
described52. Briefly, the ‘sum rule’ (which is an extension of the pigeonhole principle 753 
described in Ref 11), asserts that if a subclone A is ancestral to both subclones B and C and 754 
if the summed CCFs of B and C exceed the CCF of A in any sample, the relationship 755 
between the subclones must be linear. The ‘crossing rule’ is applied to tree construction 756 
from multiple samples. It asserts that if the CCF of B is higher than the CCF of C in sample X 757 
and the CCF of B is lower than the CCF of sample C in sample Y then B and C must be in 758 
separate branches of the phylogenetic tree, i.e. they are not collinear. For all clonally 759 
related samples, the same underlying phylogenetic tree must exist. This exerts much 760 
greater stringency to the inferred ordering of subclonal clusters present in more than one 761 
sample and defines their position on the phylogenetic tree unequivocally. Note that P9 762 
contains two independent cancers derived from Barrett’s esophagus and adenocarcinoma 763 
regions. CCF values are reported relative to the dominant cancer, so in P9_D4, which 764 
contains both cancers, the two cancers are reported with CCFs of 100% and 69%. This 765 
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apparent violation of the sum rule results from the mathematical convenience of 766 
normalizing to the dominant cancer. 767 
It should be noted that the sum rule and crossing rule only strictly apply when the infinite 768 
sites assumption (ISA) is obeyed. The ISA states that each mutation only occurs once during 769 
the lifetime of a tumor and that mutations never revert to normal. A recent study53 has 770 
shown, through analysis of targeted sequencing of single cells , that the ISA is not always 771 
followed in real data, for two reasons: 772 
• Copy number alterations (CNAs), specifically losses and loss of heterozygosity, 773 
have the effect of removing mutations in the deleted region, resulting in the 774 
apparent ‘reversion’ of a mutation. 775 
• The same mutation may occur on more than one occasion, particularly if the 776 
mutation is a driver mutation. 777 
In our study, we take account of CNAs when calculating the CCF of each mutation. In 778 
regions that have undergone gain of one or both alleles, a mutation may be present on 779 
more than one chromosome copy, up to the number of copies of the most amplified 780 
chromosome copy. Conversely, if one or both chromosome copies have undergone loss in 781 
a particular sample, a mutation may be lost in that sample. In the situation where a 782 
mutation is unobserved in a sample and that sample has a copy number state lower than 783 
that observed in another sample in which the mutation is observed, we do not call the 784 
mutation as absent. Rather, we cluster it based on its CCF in the remaining samples, 785 
treating its CCF in the target sample as unknown.  786 
 787 
Identification of cancer cell fraction 788 
For each mutation we calculated the mutation copy number as previously described, using 789 
the mutant allele burden, tumor cellularity and locus specific copy number in the tumor 790 
and matched normal49. The mutation copy number reflects the percentage of tumor cells 791 
within a sample carrying that mutation, and permits the cross-comparison of the mutation 792 
in related samples despite differences in tumor purity and/ or copy number profiles. 793 
Mutations present on multiple copies of a chromosomal segment will have a mutation 794 
copy number greater than 1. To group mutations according to the percentage of cells 795 
containing it, or cancer cell fraction (CCF), the number of chromosomes carrying the 796 
mutation must be determined. For all mutations within amplified regions with a major 797 
27  
allele copy number, the observed fraction of mutated reads was compared to the expected 798 
fraction of mutated reads resulting from a mutation present assuming a binomial 799 
distribution37. 800 
 801 
Annotation of the trees with mutations 802 
We annotated each tree with oncogenic or putative oncogenic alterations including 803 
substitutions and copy number changes. For substitutions, cluster assignment information 804 
from a multidimensional Dirichlet process was used. 805 
For rearrangements and copy number changes, branch assignment was achieved by 806 
considering the set of samples containing the variant and the subclonal fraction of the 807 
associated copy number segment where applicable. All potential driver alterations were 808 
annotated. For substitutions, structural variants and copy number events, these included a 809 
set of genes compiled from the TARGET database from the Broad Institute and multiple 810 
sequencing datasets for OAC14-16,18,19. 811 
 812 
Shallow Whole Genome Sequencing for Subclone Identification 813 
For shallow whole genome sequencing, samples were sequenced to a median depth of 814 
~1x. It was not therefore feasible to call mutations de novo for these samples, but we were 815 
able to count the number of mutations from each subclone that reported a mutant read in 816 
1x WGS sequencing. We performed simulations of 1x WGS data in order to ascertain the 817 
correlation between the number of mutations identified and the CCF of each subclone. 818 
First, we simulated subclones with CCF values between 0.01 and 1.00, assuming 1000 819 
mutations per subclone, sequencing depth drawn from a Poisson distribution with 820 
expected value 1, and binomial sampling of WT and mutant reads. The correlation 821 
between the number of mutations detected and the CCF of the subclone was very high 822 
(Pearson r = 0.992, Extended Data Fig. 4). In order to test whether subclones containing 823 
fewer mutations also had good correlations between CCF and number of detected 824 
mutations, we performed further simulations of subclones containing between 50 and 825 
1,000 mutations and ascertained that the correlation remained very high (> 0.997) for 826 
cluster sizes as small as 200 (Extended Data Fig. 5). Of the 169 subclones identified in our 827 
study, only two contained fewer than 200 mutations, indicating that the number of 828 
28  
mutations detected is a good proxy for the CCF of a subclone. 829 
SNVs from libraries sequenced to a minimum of 1x following filtering, were allocated to 830 
subclones previously identified at 50x WGS. Mapping quality and base quality of 10 were 831 
used. This resulted in tabulated counts for SNVs being allocated to subclones identified at 832 
50x WGS for each sample. Normalization was performed according to the number of SNVs 833 
assigned to each subclone from 50x WGS, and to the total number of SNVs in that sample 834 
in order to account for potential differences in coverage, using the following equation: 835 
CCFcluster = ncluster/ntruncal × Htruncal /Hcluster 836 
in which ncluster and ntruncal are the numbers of loci in the target cluster and the truncal 837 
cluster that have mutant reads in the target sample and Hcluster and Htruncal are the number 838 
of mutations identified from 50x WGS in the target and truncal clusters. For each 1x WGS 839 
sample, this provides an estimate of the CCF of each subclone within that sample. 840 
In all cases, near equal coverage was obtained and in cases of low cellularity further 841 
sequencing was performed in order to achieve this. After normalization, the GENE-E 842 
package (https://software.broadinstitute.org/GENE-E/download.html) was used to cluster 843 
the 1x WGS samples according to the similarity of their CCF profiles using Pearson 844 
correlation.  845 
 846 
Data Availability 847 
Sequencing data that support the findings of this paper have been deposited in the 848 
European Genome-phenome Archive with the accession code EGAD00001005434.  849 
 850 
Code Availability  851 
All code required to reproduce the analysis outline in this manuscript can be found in the 852 
main and supplementary methods. There are no restrictions to the accessibility of this code.  853 
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Diaspora Model of Metastatic Spread
Features of Diaspora
DEFINING ASSOCIATED
Case Mul2ple	  subclones	  from	  
primary	  spread	  to	  
mul2ple	  metasta2c	  sites
	  
Stellate	  pa@ern	   
of	  three	  or	  more 
subclones 
derived	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the	  same	   
ancestor	  found	   




























P1 ✓ 	  	  	  	  	  × ✓ *✓ ×
P2 ✓ ✓ ✓ ✓ ✓
P3 ✓ 	  	  	  	  	  	  × 	  	  	  	  	  × ✓ ✓
P4 ✓ ✓ ✓ ✓ ✓
P6 ✓ ✓ ✓ ✓ ✓
P8 ✓ ✓ 	  	  	  	  	  × *✓ 	  ×	  
P9 ✓ ✓ 	  ×	   ✓ ×
P10 ✓ 	  	  	  	  	  × ✓ ✓ 	  	  	  	  	  	  ×
S3 	  	  	  	  	  	  × 	  	  	  	  	  × 	  	  	  	  	  × 	  	  	  	  	  	  	  × ✓
S4 ✓ ✓ ✓ ✓ ✓
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